Accreditation Agency’s contribution to HTA


       The delegate of State Health Care Accreditation Agency under the Ministry of Health (hereinafter – Accreditation Agency) has participated in the 8th meeting of HTA Network in Brussels, March 2017. The network has been established by European Commission in 2013. The main purpose of this meeting - to discuss strategic issues of health technology assessment (HTA) in Europe – whether EU countries are willing to contribute to a sustainable collaboration on HTA beyond 2020. Accreditation Agency represents Lithuania in HTA Network since the establishment of the network and aims to contribute to the policy development related to HTA at European level.

       HTA Network supports and facilitates EU cooperation between national authorities or bodies responsible for HTA designated by the EU countries and Norway. This network has been established by European Commission in 2013. The major aim of the network - to maintain and develop sustainable, effective, rational and transparent national health care systems in EU countries and as the main tool to achieve the best result is HTA.

       HTA is referred to as unbiased, objective, comprehensive data analysis on various current or new (innovative) health technologies, i.e. therapeutic, in vitro diagnostic, medical imaging, surgical devices, medical procedures, pharmaceuticals etc. HTA reports include clinical data addressing benefits and risks, direct and intended effects versus indirect and unintended consequences of the technology, as well as economic impact, e.g. value, cost-effectiveness, feasibility and profitability. HTA provides information to many different types of stakeholders including patients, health care professionals, decision-makers and politicians, playing a critical role in health affairs, especially considering capital investments, healthcare delivery and coverage issues.

       There are approximately 40 institutions providing HTA in Europe. Some countries have more than one HTA organization, i.e. Austria, United Kingdom, Germany, Italy and Spain. European Commission is highly dedicated to merge these financial and human resources and develop a sustainable collaboration between national authorities or bodies responsible for HTA in Europe. Such joint actions at European level would lead to developing common methodology, capacity building, pooling resources and avoiding duplication in the assessment of the same product or intervention.

       European Commission has recently launched a public consultation on strengthening EU cooperation on HTA and a number of studies in order to reveal whether EU countries are willing to contribute to a sustainable collaboration beyond 2020 and to provide further evidence for the analysis of possible options and their impacts. Views have been gathered from stakeholders including HTA bodies, industry, patients' representatives, health organizations and national or regional health authorities. Total number of replies to the public consultation reached approx. 250.

       European Commission has reflected draft results of the public consultation in the 8th HTA Network meeting. It was stated that 98 % of EU citizens and 96 % of public administrations questionnaired consider HTA is useful and important. Totally there have been outlined 5 policy options for EU cooperation on HTA beyond 2020. Draft results revealed that option “Voluntary participation + mandatory uptake of joint assessments for the participants” is recognized as the most preferred. Final proposal of EU cooperation on HTA, covering adequate financing model and the main guiding (governance) principles, is scheduled to be announced in the 4th quarter, 2017.

       Accreditation Agency has been assigned to organize and conduct HTA of medical devices at national level since 2011. Accreditation Agency has already conducted 18 HTA reports concerning new and innovative medical devices, especially in the field of oncology, cardiology, endocrinology, neurology. In terms of HTA impact, the results revealed that most of new (innovative) technologies assessed were identified as ineffective and/or unsafe or low value-for-money technologies.

       “Accreditation Agency is aiming to make a significant input in strategic and political decisions regarding HTA at European level, as well as to protect our patients from unsafe or ineffective medical devices and to inform politicians concerning decisions on innovations, capital investments and healthcare coverage issues“, – says Nora Ribokienė, director of Accreditation Agency.

       More information about HTA reports conducted by Accreditation Agency here.


Informacija atnaujinta 2017-05-05



prie Sveikatos apsaugos ministerijos

A. Juozapavičiaus g. 9,
LT-09311 Vilnius
Tel. (8 5) 261 5177 ,
Faks. (8 5) 212 7310 ,
El. paštas:

Biudžetinė įstaiga,
Juridinių asmenų registras,
Kodas 191352247

Darbo laikas:

I - IV 8:00 - 17:00
V 8:00 - 15:45
Pietų pertrauka 12:00 - 12:45

Konsultacijos telefonu

Priimamojo darbo grafikas

Kaip mus rasti?